SNDX - Company ID 0001395937
The table below shows Syndax Pharmaceuticals Inc's balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $134.93M | $154.08M | $295.39M | $74.36M | $221.97M | $115.24M |
| Short-term investments | $259.14M | $418.80M | $275.30M | $401.45M | $217.97M | $177.82M |
| Receivables | $38.00M | $7.60M | - | - | - | - |
| Inventory | $32.75M | $366.00K | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $528.08M |
| $603.06M |
| $580.88M |
| $489.79M |
| $448.40M |
| $298.86M |
| Property, plant & equipment | $181.00K | $0.00 | $8.00K | $20.00K | $278.00K | $192.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $529.71M | $724.82M | $612.88M | $497.24M | $449.66M | $300.61M |
| Accounts payable | $16.58M | $11.63M | $9.96M | $4.35M | $5.67M | $3.51M |
| Total current liabilities | $120.12M | $103.55M | $58.10M | $29.07M | $20.68M | $18.87M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $465.08M | $436.69M | $58.68M | $29.79M | $41.29M | $48.42M |
| Retained earnings | -$1.51B | -$1.22B | -$902.40M | -$693.04M | -$543.70M | -$568.63M |
| Total equity | $64.63M | $288.12M | $554.20M | $467.45M | $408.37M | $252.19M |